Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05353790
Other study ID # IRB-2021-67
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date October 11, 2021
Est. completion date June 6, 2024

Study information

Verified date February 2024
Source Clinical Nutrition Research Center, Illinois Institute of Technology
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The research is designed as a randomized, 2-arm, parallel, controlled, human clinical trial to investigate the effects of avocado and mango consumption for 8 weeks on indices of macro- and micro- vascular function in individuals with prediabetes. FMD of the brachial artery, pulse wave velocity (PWV), central blood pressure (cBP), and Optical Coherence Tomography Angiography (OCTA) of the eye will be used for vascular assessments. The research plan will also explore cognitive and kidney function benefits of regular avocado and mango intake using specified cognitive tasks and kidney function biomarkers


Description:

Recruited subjects must meet all eligibility criteria, sign and date a written Institutional Review Board (IRB)-approved Informed Consent Form. The trial will test 2 dietary conditions which will be fresh fruit (1 avocado and 1 mango) compared to a control arm matched in calories (but not macronutrients or fiber) equivalent to 1 fresh Hass avocado + 1 cup of mango per day. Participants will be given general meal plans, including specific foods assnacks or meals to include in their diet daily. - Pre-Screening To learn more about the study and to pre-qualify, potential subjects can call the CNRC or visit the website posted on recruitment flyers or from other recruitment materials. If they call the CNRC, a staff member will provide a brief background on the study and ask a series of questions from a pre-screening questionnaire to see if they may be eligible to participate. The same questionnaire is available on the website and can be filled out by potential subjects online. The pre-screening questionnaire includes self-reported information about health status and lifestyle factors that can be used to determine if someone is not eligible for the study. - Information Session and Screening Session Information Session and Screening Visit may occur simultaneously or Information Session may occur prior to Screening Visit. Prior to the Screening Visit, potential subjects will be asked to arrive at the CNRC after an overnight-fast (stop eating after 10 pm) and be well-hydrated. Subjects should aim for drinking at least 8-10 cups of water the 24 h prior to the Screening Visit. Information Session: At the CNRC, pre-screened subjects will participate in an Information Session where they will be informed of all study procedures and study schedules. If willing to adhere to all study procedures and schedules, they will be asked to read, ask questions, signand date the Institutional Review Board (IRB) approved Informed Consent Form (ICF) before any laboratory or study screening procedures begin. Screening Visit: After meeting eligibility criteria for blood glucose (BG) and blood pressure (BP) measures, subjects will advance to further screening procedures which will include a comprehensive chemistry panel plus TSH, anthropometric measurements (height, weight, waist circumference, body composition), BMI (calculated from height and weight), medical history, prior and concomitant medication, and dietary supplements use, and completion of a series of questionnaires relating to their general health and lifestyle. After confirming eligibility through blood test results, subjects will then be scheduled for a visit to the Illinois Eye Institute (IEI) for a screening eye exam. During this exam, drops to check the eye pressure and drops to dilate eyes will be used. Based on study eligibility criteria subjects may be invited to participate in the study. A Pre-Study Visit and all Test Day Visits will be scheduled before leaving the CNRC or shortly thereafter. -Pre-Study Visit, Randomization, and Cognitive assessment The pre-study visit is for training on various aspects of the study. In addition, subjects will be randomized for more specific study protocol information (eg., dietary inclusion of study foods). The Pre-Study Visit will also include a baseline cognitive function test. This will include visiting instructions for preparing for the cognitive test (eg., fasting instructions, waiting to eat breakfast and having morning coffee/tea at the clinic, etc). Each subject will come to the CNRC in fasting (10 hours) state for one pre-scheduled Pre-Study Visit, where they will receive a breakfast meal to consume onsite and complete the baseline cognitive testing and then proceed to instructions on the process for completing various aspects of the research protocol, including but not limited to, the online 24 h dietary recalls (via ASA24 program), weekly visits for food pick up, incorporating foods into diet, plan for eye exams, and more. They will also be provided with all study instructions for fasting before each major test day, completing check-off diaries to help with study compliance, text/email verification receiving appointment reminders, etc. Test Day Visits: All subjects will report to the CNRC on a weekly basis unless conditions outside our control require less frequent person-to-person interaction. In this case, however, alternatives mechanisms will be instituted to ensure contact with subjects and delivery of the product. Visit 1, Visit 5, and Visit 9 will have two phases (a visit at IEI & b visit at CNRC). specifically, subjects will go to the IEI for collection of the OCT-A images (Visit 1a, 5a, and 9a) 1-5 days prior to the visit at CNRC. Visits at CNRC: Visit 1b, Visit 5b, and Visit 9b encompass all study procedures (except for the cognitive battery, which is performed at Pre-Study and Visit 8). A fasting blood sample, FMD, PWV, cBP, anthropometrics, and 24 h recall will all be assessed. Subjects will be given a standardized breakfast and the FMD repeated 1.5 h later. Thereafter, subject will be given groceries and study-specific food products and reminded how to include in their diet. A Test Day Visit Questionnaire to report compliance with study instructions (after first visit), dietary tolerance and general health status (any illnesses in the 7 days before the Test Day Visit), change in meds, will be given/collected. To minimize vascular and metabolic variability due to hormone fluctuations associated with the menstrual cycle women will be studied in the follicular phase of their menstrual cycle. The 8-week intervention allows for scheduling individuals' females accordingly. For subjects willing to return 2 months after discontinuing treatment, Visit 9 will be repeated for follow-up. This visit will not be considered part of "completer" analysis but will provide insight for research and study designs. Blood Donation Guidelines indicated that for each subject no more than 550 mL of blood be collected in a 56-day period. The amount of blood collected in this study will be far below donation guidelines (~70 mL) over the course of the study. -Food pick up days (CNRC, IllinoisTech) Bodyweight, compliance records, general health questionnaire, and dietary tolerance questionnaire will be completed. Food provided per randomization. Meal plans. Four one-week meal plans for each Active and Control intervention will be developed and given twice in random order to allow for a partially controlled dietary regimen.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 80
Est. completion date June 6, 2024
Est. primary completion date December 6, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 25 Years to 70 Years
Eligibility Inclusion Criteria: - Men or women, age 25-70 year- Fasting blood glucose concentration between 100 mg/dL and 125 mg/dL at screening visit - Blood pressure 120-160 mmHg systolic or 80-100 mm/Hg diastolic at screening visit - Nonsmokers (past smokers can be allowed if they have abstinence for minimum of 12 months) - Judged to be in good health on the basis of the medical history (i.e., no clinical evidence of cardiovascular, metabolic, respiratory, renal, gastrointestinal or hepatic disease - Not taking any medications that would interfere with outcomes of the study, (e.g., lipid lowering medications, anti-inflammatory drugs, dietary supplements, etc.) - Able to provide informed consent - Able to comply and perform the procedures requested by the protocol (follow the dietary plans, come to scheduled visits, record food intake in a diary, complete questionnaires, provide blood samples and complete other tests (eye and brain/cognitive function) - Able to maintain usual physical activity pattern - Able to abstain from alcohol consumption and avoid vigorous physical activity for 24 hours prior to and during study visit Exclusion Criteria: - Men and women who have blood pressure >160 mmHg (systolic)/100 mmHg (diastolic) at screening visit - Men and women who have fasting blood glucose concentration <100 or >125 mg/dL at screening visit - Abnormal Thyroid-stimulating Hormone (TSH) at screening visit - Men and women with diabetes - History of cardiovascular event, respiratory, renal, gastrointestinal, hepatic or eye disease or surgery (e.g., heart failure, myocardial infarction, stroke, angina, related surgeries, etc.) that, in the opinion of the investigator, could interfere with the interpretation of the study results. - High refractive error (+/- 6.00 D, axial length greater than 26 mm or less than 22mm), astigmatism >3.00D, impaired vision/not correctible to 20/20, high eye pressures (>21 mmHg) and narrow angles (< grade 3 Van Herick) in the study eye as confirmed by screening eye exam at IEI screening visit - Head injury in past 6 months - Men and women with cancer other than non-melanoma skin cancer in previous 5 years - Taking medication or dietary supplements that may interfere with the outcomes of the study, (e.g., antioxidant supplement, anti-inflammation, lipid-lowering medication, blood pressure-lowering medication, etc.). Subjects may choose to go off dietary supplements (requires 30-day washout; e.g., fish oil, etc.) - Vegan or other extreme dietary regimens (e.g., Atkins diet, etc.) as judged by the investigator - Known or suspected intolerance, allergies or hypersensitivity to study foods or treatments - Current smoker or smoked/vaped within the last 12 months - Unstable weight: Actively losing or gaining weight or trying to lose or gain weight. Gained or lost weight +/- 5 kg (11 lbs.) in previous 2 months. - Substance (alcohol or drug) abuse within the last 2 years - Present with significant psychiatric or neurological disturbances - Women who are known to be pregnant or who are intending to become pregnant over the course of the study - Women who are lactating - Major trauma or a surgical event within 2 months or longer depending on trauma or event and after consultation with PI. - Has used antibiotics within the previous 2 months - History of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge eating) diagnosed by a health professional - Excessive coffee and tea consumers (> 4 cups/d) - Donated blood within last 3 months - Men and women who do excessive exercise regularly or are an athlete - Women who are taking unstable dose and brand of hormonal contraceptives and/or stable dose and brand less than 6 months - Unusual working hours (e.g., working overnight; 3rd shift)

Study Design


Intervention

Other:
Meals + snacks: control
8 weeks meal plans matched in calories (but not macronutrients or fiber) equivalent to 1 avocado + 1 cup of mango per day
Meals + snacks: Avocado mango
8 weeks meal plans provide1 avocado + 1 cup of mango per day

Locations

Country Name City State
United States Clinical Nutrition Research Center Chicago Illinois

Sponsors (3)

Lead Sponsor Collaborator
Clinical Nutrition Research Center, Illinois Institute of Technology Hass Avocado Board, National Mango Board

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in vascular function measured by Flow-mediated vasodilation of brachial artery Macro-vascular assessment by Ultrasonography baseline-8 weeks
Primary Changes in Pulse Wave Velocity fasting state, Macro-vascular assessment by SphygmaCor technology: baseline-8 weeks
Primary Changes in Central Blood pressure fasting state, Macro-vascular assessment by SphygmaCor technology: baseline-8 weeks
Primary Changes in plasma biomarkers:fasting glucose Randox automated clinical analyzer baseline-8 weeks
Primary Changes in plasma biomarkers: fasting insulin Randox automated clinical analyzer baseline-8 weeks
Primary Changes in plasma biomarkers:lipid profile Randox automated clinical analyzer, total cholesterol,LDL cholesterol, HDL cholesterol, triglycerides baseline-8 weeks
Primary Changes in plasma biomarkers and measures of inflammation concentration: IL-6 IL-6 (ELISA, RnD systems) baseline-8 weeks
Primary Changes in plasma biomarkers and measures of inflammation concentration: ICAM ICAM (ELISA, RnD systems) baseline-8 weeks
Primary Changes in plasma biomarkers and measures of inflammation concentration: VCAM VCAM (ELISA, RnD systems) baseline-8 weeks
Primary Changes in plasma biomarkers and measures of brain-derived neurotrophic factor: BDNF BDNF (ELISA, RnD systems) baseline-8 weeks
Primary Changes in plasma biomarkers and measures of brain-derived neurotrophic factor: IGF1 IGF1 (ELISA, RnD systems) baseline-8 weeks
Primary Changes in Kidney function markers serum creatinine baseline-8 weeks
Secondary Changes in Foveal Avascular Zone area Microvascular assessment by OCT-A baseline-8 weeks
Secondary Changes in Vascular Density superficial and deep Microvascular assessment by OCT-A baseline-8 weeks
Secondary Changes in Vascular branch number Microvascular assessment by OCT-A baseline-8 weeks
Secondary Changes in Cognitive Function Wide Range Achievement Test-4th Edition, Reading Subtest (WRAT-4 Reading) baseline-8 weeks
Secondary Changes in Cognitive Function-1 California Verbal Learning Test-2nd Edition (CVLT-II), including short and long delays baseline-8 weeks
Secondary Changes in Cognitive Function-2 Wechsler Adult Intelligence Scale-4th Edition, Matrix Reasoning subset (WAIS-IV MR baseline-8 weeks
Secondary Changes in Cognitive Function-3 Trail Making Test A & B baseline-8 weeks
Secondary Changes in Cognitive Function-4 WAIS-IV Digit Span subtest (DS) baseline-8 weeks
Secondary Changes in Cognitive Function-5 Stroop baseline-8 weeks
Secondary Changes in Cognitive Function-6 Verbal Fluency Task (FAS & Animals) baseline-8 weeks
See also
  Status Clinical Trial Phase
Completed NCT05712005 - Cognitive Testing in Diverse Populations to Further the Objective and Clinical Understanding of Cognivue Study
Completed NCT05343208 - Effectiveness of Online Therapy to Prevent Burnout N/A
Active, not recruiting NCT05143294 - Conectar Jugando: Board Games in Elementary Classrooms (6-12 Years Old) to Improve Executive Functions N/A
Completed NCT05267730 - Conectar Jugando: Board Games in Rural Elementary Classrooms (6-12 Years Old) to Improve Executive Functions N/A
Completed NCT03987477 - Online Intervention to Modify Interpretation Biases in Depression N/A
Completed NCT03695003 - Cognitive Effects of Sage in Healthy Humans N/A
Completed NCT05075850 - Multicenter Sub-study for LAANTERN Registry NCT02392078 That Will Include Comprehensive Neuropsychological Assessment Data Collection
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Completed NCT03674281 - The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System N/A
Completed NCT03689348 - Acute and Chronic Effects of Avena Sativa on Cognition and Stress N/A
Active, not recruiting NCT05229705 - Exercise in Older Adults at Risk for Type 2 Diabetes N/A
Suspended NCT05001789 - Cognitive Functioning in Opioid Use Disorder N/A
Terminated NCT03337282 - Incidence and Characteristics of Postoperative Cognitive Dysfunction in Elderly Quebec Francophone Patients
Recruiting NCT05014399 - Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
Completed NCT03657537 - Effects of Ketone Bodies on Cognition in Type 2 Diabetes Phase 1
Completed NCT05543811 - The Influence of Food for Special Dietary Use - Spread Enriched With 5-hydroxytryptophan, Theanine and Gamma-aminobutyric Acid on Psychophysiological Functions of Subjects Without Meaningful Organic and Cognitive Pathology N/A
Recruiting NCT05699226 - Amplitude Titration to Improve ECT Clinical Outcomes N/A
Recruiting NCT05026541 - Resilience to Sleep Deprivation and Changes in Sleep Architecture in Shoonya Meditators N/A
Active, not recruiting NCT03255499 - Efficacy of the MovinCog Intervention in Children N/A
Not yet recruiting NCT06252376 - Effects of Blood Pressure on Cognition and Cerebral Hemodynamics in PD N/A